Diwakar Gupta to join Alkem Labs as Independent Director

Published On 2025-06-18 09:03 GMT   |   Update On 2025-06-18 09:03 GMT

MaharashtraAlkem Labs has announced the appointment of Diwakar Gupta as Additional Director designated as an Independent Director on the Board of Directors of the Company for a term of 5 (five) consecutive years, with effect from 13th July, 2025 upto 12th July, 2030.

"we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 18th June, 2025 based on recommendation of Nomination and Remuneration Committee and subject to the approval of shareholders of the Company, approved the appointment of Mr. Diwakar Gupta (DIN: 01274552) as Additional Director designated as an Independent Director on the Board of Directors of the Company for a term of 5 (five) consecutive years, with effect from 13th July, 2025 upto 12th July, 2030," Alkem Labs stated in a BSE filing.

Diwakar Gupta is a career banker with over 50 years of experience in banking and financial services. He is currently serving as a Non Executive Chairman of National Asset Reconstruction Company Limited and a Senior Advisor with True North, a leading India-focused PE fund. He is also serving as an Independent Director on the Boards of CRISIL Ratings Ltd, CRISIL ESG Ratings & Analytics Ltd., Mahindra Holidays & Resorts India Ltd. and its Finland based subsidiary, Holiday Club Resorts Oy, Mahindra Susten, Mahindra & Mahindra Financial Services Ltd., and SMFG India Credit Company (erstwhile FICC).

He has been closely associated with the RBI and various other governmental agencies throughout his career.

Read also: Cybersecurity incident at Alkem Labs US arm, investigation underway

Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, Ophthalmology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News